Insider trade

Officer sold ~$50K of EW shares in the open market

Traded May 18, 2026 · Filed May 18, 2026

~$50K
Reported value · 620 sh @ $81.14: 40K
Holds after · shares reported: +3.4%
stock since the trade · S&P 500 +3.4%, $82.39 → $85.19 on Oct 1

Why it stands out

Edwards Lifesciences's CVP, TAVR sold $50K of Edwards Lifesciences shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 18, 2026
Reporting period: Not applicable
Filed with the SEC: May 18, 2026

Officer$25K–$100KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$50,307

Shares × reported transaction price

Timing vs results

25 days after results of Apr 23, 2026, 66 days before results of Jul 23, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $82.39 on May 18, 2026, 13% above its 52-week low and 5% below its high, after a 1% rise over the previous 30 trading days

52-week range $72.65 (Oct 16, 2025) to $87.18 (Mar 2, 2026), 67% of the way up, from 251 adjusted closes. 30 trading days earlier: $81.19 on Apr 6, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.

Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+6.5%	+2.3%	+4.3%
30 days	+6.3%	+1.8%	+4.6%
90 days	+10.5%	+5.3%	+5.2%

Past results only. Not a forecast.

Source receipt

Record ID: 0001225208-26-005464
Filed / recorded: May 18, 2026, 9:29 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Edwards Lifesciences Corp
Issuer CIK: 1099800
Ticker: EW
Reporting person: Daniel J. Lippis
Relationship: Officer
Officer title: CVP, TAVR
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: May 18, 2026
Transaction code: S
Shares / units: 620
Price per share: $81.14
Acquired / disposed: Disposed (D)
Shares owned after: 40,410.9103
Ownership form: Direct
Amendment: No

Footnotes from the filing

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.

Around the same time

Officer sold4mo ago

~$49KReported value · 567.53 sh @ $86.08

Edwards Lifesciences's SVP, Corporate Controller sold $49K of Edwards Lifesciences shares. Nobody planned it ahead of time.

Why it stands out Official record

Officer sold4mo ago

~$2MReported value · 23K sh @ $86.4201

Edwards Lifesciences's CVP,Strategy/Corp Development sold $2M of Edwards Lifesciences shares. Nobody planned it ahead of time.

Why it stands out Official record

Officer sold5mo ago

~$127KReported value · 1,500 sh @ $84.6035

Edwards Lifesciences's CVP, TMTT & Surgical sold $127K of Edwards Lifesciences shares. Nobody planned it ahead of time.

Why it stands out Official record